肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Sci Rep：靶向PAK4化合物有望用于胰腺癌治疗

2017-02-19 MedSci MedSci原创

胰腺癌PAK4
关注

一项新的研究证实了称为PAK4的蛋白质在胰腺癌细胞的运动和生长中的作用，可以帮助研究人员找到解决这种疾病的新方法。这项工作由国家慈善胰腺癌研究基金资助，发现了新的证据表明，PAK4使癌细胞生长和从胰腺扩散到身体的其他部位，在转移的过程中发挥关键作用。来自伦敦国王学院的研究人员也发现了PAK4与一种被称为磷酸肌醇3-激酶途径（PI3K）的癌症途径之间的密切关系的证据。PI3K负责调节癌细胞的生长和存

已证实流氓蛋白PAK4在<a class=胰腺癌细胞中的作用" style="border: 0px; max-width: 100%; display: block; margin: 10px auto;">

一项新的研究证实了称为PAK4的蛋白质在胰腺癌细胞的运动和生长中的作用，可以帮助研究人员找到解决这种疾病的新方法。

这项工作由国家慈善胰腺癌研究基金资助，发现了新的证据表明，PAK4使癌细胞生长和从胰腺扩散到身体的其他部位，在转移的过程中发挥关键作用。

来自伦敦国王学院的研究人员也发现了PAK4与一种被称为磷酸肌醇3-激酶途径（PI3K）的癌症途径之间的密切关系的证据。PI3K负责调节癌细胞的生长和存活，并且已经开发了靶向其的几种抑制剂。

“我们已经看到PAK4和PI3K通路是联系在一起的，但是发现他们相互作用的证据是一个重要的进步，我们因此发现了解决这种疾病的有希望的新的抑制剂化合物”。

这项工作补充了对PAK4的现有研究，通过使用更好地模拟胰腺肿瘤的复杂模型系统，改进了现有知识。

该团队还研究了当PAK4从细胞中去除时发生了什么。

“这种技术使我们能够详细了解细胞的结构和发育，我们可以清楚地看到，如果从这些细胞中去除PAK4，它们就失去了侵袭的能力，”Wells博士解释说。

Wells博士补充说：“胰腺癌的一个重要问题是复发 - 即使对于可以手术的患者，也有非常高的复发率。如果我们可以开发抑制细胞移出胰腺的治疗方案，可以在手术后给予患者，并有助于预防该疾病的复发和传播。”

最终，该研究证实PAK4是新药物化合物的有希望的靶标，其中许多已经被研究人员鉴定用于测试。该团队还计划进一步研究，以了解更多关于胰腺癌细胞为什么依赖于PAK4。

原始出处：

Rane C, Senapedis W, Baloglu E, Landesman Y, Crochiere M, Das-Gupta S, Minden A. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth. Sci Rep. 2017 Feb 15;7:42555. doi: 10.1038/srep42555.


King H, Thillai K, Whale A, Arumugam P, Eldaly H, Kocher HM, Wells CM. PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration. Sci Rep. 2017 Feb 16;7:42575. doi: 10.1038/srep42575.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-04-17 wangyang7958

    #化合物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-20 1e10c84am36(暂无匿称)

    文章真心不错耶

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-19 tianxing1991

    新的靶点，价值有待进一步研究…

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-19 忠诚向上

    好好努力

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-19 九九消寒

    新发现，新治疗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-19 flysky120

    希望能好好用在患者上

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-19 1e145228m78(暂无匿称)

    很有希望的治疗方法，谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1906334, encodeId=76b3190633468, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Apr 17 16:41:00 CST 2017, time=2017-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177086, encodeId=bc151e70861f, content=文章真心不错耶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Feb 20 08:23:13 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177024, encodeId=ef321e70241c, content=新的靶点，价值有待进一步研究…, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/03/59e5dddddcc99371882a5fec727b75ec.jpg, createdBy=e55f1732520, createdName=tianxing1991, createdTime=Sun Feb 19 23:08:19 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176982, encodeId=683e1e6982e2, content=好好努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 19 15:03:16 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176946, encodeId=6c5d1e6946aa, content=新发现，新治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sun Feb 19 11:10:47 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176945, encodeId=745e1e69451a, content=希望能好好用在患者上, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 19 10:59:10 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176944, encodeId=b29d1e6944e1, content=很有希望的治疗方法，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Feb 19 10:57:00 CST 2017, time=2017-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176939, encodeId=cded1e69395f, content=感谢分享！学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sun Feb 19 10:11:23 CST 2017, time=2017-02-19, status=1, ipAttribution=)]
    2017-02-19 laymankey

    感谢分享！学习了！

    0

相关资讯

LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效

ESPAC-3试验显示，胰腺癌切除的术后患者，辅助性吉西他滨与佐剂5-氟尿嘧啶/亚叶酸一样具有相似的生存效果，但具有更小的毒性的标准治疗。另一些临床试验显示，在晚期或转移性胰腺癌中，与单独的吉西他滨相比，吉西他滨和卡培他滨联合具有更好的存活和肿瘤反应。近期，一项发表在权威杂志LANCET上的研究了吉西他滨和卡培他滨与吉西他滨单药治疗在切除胰腺癌的患者中的疗效和安全性。研究者们在英格兰、苏格兰、威尔

Oncogene：RET的上调诱导胰腺癌的神经束浸润

沿着神经扩散的肿瘤是一种神经周围入侵的现象，其在包括胰腺导管腺癌（PDAC）的各种癌症中十分常见。神经浸润与肿瘤的不良结局相关，但其具体机制仍不清楚。近期，一项发表在Oncogene杂志上的研究使用转基因Pdx-1-Cre / KrasG12D / p53R172H（KPC）小鼠模型，研究者们研究了PDAC神经入侵的机制。为了检测影响癌细胞的神经浸润的组织特异性因素，研究者们在Cx3cr1、GDN

Nature杂志1月不得不看的亮点研究

不知不觉，1月即将结束了，在即将过去的1月里Nature杂志又有哪些亮点研究值得阅读呢？小编对此进行了整理，与各位一起学习。

Clin Cancer Res：血液中肿瘤DNA可作为胰腺癌的预后标志物

从胰腺癌患者的血液样品中分离的循环肿瘤DNA（ctDNA）与不良结果相关。 法国巴黎的索邦大学胃肠病学和消化肿瘤科的Jean-Baptiste Bachet博士和同事，将这项研究发表在临床癌症研究中。 胰腺癌的发病率在西方国家有所上升，预后仍然很差。Bachet指出，预计到2030年，胰腺癌将在肺癌之后成为美国癌症相关死亡的第二大原因，因此被认为是一个公共卫生问题。 Bachet

胰腺癌治疗新希望

胰腺癌早期诊断很困难，而且缺乏特异的药物。近期，来自法国和西班牙的研究人员发现，一种已经用于治疗焦虑症的物质能够干扰胰腺癌的发展。

Nature：安德森癌症中心找到防止胰腺癌恶化的门卫蛋白

来自德克萨斯大学MD Anderson癌症中心的研究人员确定了阻止胰腺癌细胞恶化转变的门卫蛋白，同时也找到当这些门卫蛋白耗尽时阻止这些细胞恶化的治疗方法。相关文章2月8日在Nature上在线发表。他们利用来自患者的肿瘤异种移植和小鼠模型开展了一系列临床前实验，该发现有助为携带迅速恶化、对治疗有抗性的胰腺癌细胞亚群的病人开发出潜在治疗方法。